This is a non-randomised, controlled, parallel group, sub-study of D2EFT (NCT03017872), a
randomised, open-label study in approximately 1,000 HIV-infected adults failing first-line
antiretroviral therapy (ART) in low-middle income countries. The sub-study will be offered to
all D2EFT sites with access to DXA technology for whole-body composition analysis. Sites will
offer the sub-study to consecutive clinic patients. Patients must be approached for
participation and provide informed written consent prior to randomisation into D2EFT. This
study will recruit approximately 300 patients. Allocation to one of three ART treatment
regimens will follow the result of D2EFT randomisation. The study will investigate the role
of contemporary ART on body composition and metabolic parameters by comparing over 96 weeks
the effects of the D2EFT ART regimens. The primary endpoint will be assessed at week 48.